A comprehensively characterized large panel of head and neck cancer patient‐derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|136|12|2940-2948

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.136, Iss.12, 2015-06, pp. : 2940-2948

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells

By              

International Journal of Molecular Medicine, Vol. 31, Iss. 4, 2013-01 ,pp. : 904-912

Spandidos Publications

Access to resources Recommend Favorite

Patient‐derived xenografts for individualized care in advanced sarcoma

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 2006-2015

John Wiley & Sons Inc

Access to resources Recommend Favorite

Establishment of primary patient‐derived xenografts of palliative TURP specimens to study castrate‐resistant prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 13, 2015-09 ,pp. : 1475-1483

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient‐derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management

By  

HEPATOLOGY, Vol. 64, Iss. 4, 2016-10 ,pp. : 1121-1135

John Wiley & Sons Inc

Access to resources Recommend Favorite

The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross‐talk, and therapies

By  

ORAL DISEASES, Vol. 21, Iss. 7, 2015-10 ,pp. : 815-825

John Wiley & Sons Inc

Access to resources Recommend Favorite